Whole-body PBPK model of efavirenz as CYP3A4 perpetrator drug
This repository contains:
- a PK-Sim snapshot (*.json) file of the current PBPK model
- static content (e.g. text blocks, *.md files) as inputs for an evaluation plan
- an evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model
The latest release of the snapshot of the model, the evaluation plan and the static content can be found here.
The latest release of the PK-Sim project model file and the respective evaluation report can be found here.
This efavirenz model is intended to be used as perpetrator drug in CYP3A4-mediated drug-drug interactions (DDI).
This whole-body PBPK model of efavirenz has been developed using in particular published pharmacokinetic clinical data by Ogburn et al. 2010 [1], Mouly et al. 1999 [2], Xu et al. 2013 [3], Dooley et al. 2012 [4] , Garg et al. 2013 [5] and Huang et al. 2012 [6]. For the parameterization of CYP3A4 interaction, concentration-time profiles of efavirenz-midazolam interaction studies of Mikus et al. 2017 [7] and Katzenmaier et al. 2010 [8] were used.
Within this repository, we distribute a whole-body PBPK model of efavirenz, that has been carefully developed using a large number of clinical studies and evaluated within our DDI modeling network.
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.